Welcome to LookChem.com Sign In|Join Free

CAS

  • or
6-IODO-1H-QUINAZOLINE-2,4-DIONE is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

16353-27-8 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 16353-27-8 Structure
  • Basic information

    1. Product Name: 6-IODO-1H-QUINAZOLINE-2,4-DIONE
    2. Synonyms: 6-IODO-1H-QUINAZOLINE-2,4-DIONE;6-Iodoquinazoline-2,4(1H,3H)-dione
    3. CAS NO:16353-27-8
    4. Molecular Formula: C8H5IN2O2
    5. Molecular Weight: 288.04197
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 16353-27-8.mol
  • Chemical Properties

    1. Melting Point: >300 °C(Solv: 1,4-dioxane (123-91-1))
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 2.008g/cm3
    6. Refractive Index: 1.671
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. PKA: 10.03±0.20(Predicted)
    10. CAS DataBase Reference: 6-IODO-1H-QUINAZOLINE-2,4-DIONE(CAS DataBase Reference)
    11. NIST Chemistry Reference: 6-IODO-1H-QUINAZOLINE-2,4-DIONE(16353-27-8)
    12. EPA Substance Registry System: 6-IODO-1H-QUINAZOLINE-2,4-DIONE(16353-27-8)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 16353-27-8(Hazardous Substances Data)

16353-27-8 Usage

General Description

6-Iodo-1H-quinazoline-2,4-dione is a chemical compound with the molecular formula C8H4IN3O2. It is a quinazoline derivative that contains an iodine atom in its structure. 6-IODO-1H-QUINAZOLINE-2,4-DIONE has potential applications in the field of pharmaceuticals and organic synthesis. Its molecular structure makes it an important intermediate for the production of various biologically active compounds and pharmaceutical ingredients. Additionally, research has shown that 6-Iodo-1H-quinazoline-2,4-dione exhibits biological activity against certain diseases and may serve as a valuable building block for drug development. Overall, this compound has garnered attention as a versatile and promising chemical entity with potential benefits in the pharmaceutical and medical industries.

Check Digit Verification of cas no

The CAS Registry Mumber 16353-27-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,3,5 and 3 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 16353-27:
(7*1)+(6*6)+(5*3)+(4*5)+(3*3)+(2*2)+(1*7)=98
98 % 10 = 8
So 16353-27-8 is a valid CAS Registry Number.
InChI:InChI=1/C8H5IN2O2/c9-4-1-2-6-5(3-4)7(12)11-8(13)10-6/h1-3H,(H2,10,11,12,13)

16353-27-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 6-iodo-1H-quinazoline-2,4-dione

1.2 Other means of identification

Product number -
Other names 6-iodoquinazolinedione

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:16353-27-8 SDS

16353-27-8Relevant articles and documents

Synthesis and Characterization of Amidato Divalent Lanthanide Complexes and Their Use in Forming 2,4-Quinazolidinones from CO2 and 2-Aminobenzonitriles

Wang, Qianyu,Lu, Chengrong,Zhao, Bei,Yao, Yingming

, p. 2555 - 2559 (2016/06/01)

Four amidato divalent lanthanide complexes, {LnLn[N(TMS)2]THF}2 [n = 1, Ln = Eu (1); n = 2, Ln = Eu (3), Yb (4); HL1 = tBuC6H4CONHC6H3(iPr)2; HL2 = C6H5CONHC6H3(iPr)2] and {L3Eu[N(TMS)2]THF}{L32Eu(THF)2} (2) [HL3 = ClC6H4CONHC6H3(iPr)2], were synthesized and extensively characterized. This is the first time that the amidato lanthanide amides 1-4 were used to catalyze the reactions of CO2 and 2-aminobenzonitriles to form quinazoline-2,4(1H,3H)-diones at atmospheric pressure. All the complexes efficiently catalyzed the transformation, with complex 3 showing the highest activity. This catalytic system gave good to excellent yields, and good functional group tolerance. Preliminary studies were conducted to investigate the reaction mechanism.

Discovery, synthesis, and biological evaluation of thiazoloquin(az)olin(on)es as potent CD38 inhibitors

Haffner, Curt D.,Becherer, J. David,Boros, Eric E.,Cadilla, Rodolfo,Carpenter, Tiffany,Cowan, David,Deaton, David N.,Guo, Yu,Harrington, Wallace,Henke, Brad R.,Jeune, Michael R.,Kaldor, Istvan,Milliken, Naphtali,Petrov, Kim G.,Preugschat, Frank,Schulte, Christie,Shearer, Barry G.,Shearer, Todd,Smalley, Terrence L.,Stewart, Eugene L.,Stuart, J. Darren,Ulrich, John C.

, p. 3548 - 3571 (2015/05/05)

A series of thiazoloquin(az)olinones were synthesized and found to have potent inhibitory activity against CD38. Several of these compounds were also shown to have good pharmacokinetic properties and demonstrated the ability to elevate NAD levels in plasm

Synthesis and QSAR of Quinazoline Sulfonamides As Highly Potent Human Histamine H4 Receptor Inverse Agonists

Smits, Rogier A.,Adami, Maristella,Istyastono, Enade P.,Zuiderveld, Obbe P.,Van Dam, Cindy M. E.,De Kanter, Frans J. J.,Jongejan, Aldo,Coruzzi, Gabriella,Leurs, Rob,De Esch, Iwan J. P.

supporting information; experimental part, p. 2390 - 2400 (2010/09/11)

Hit optimization of the class of quinazoline containing histamine H 4 receptor (H4R) ligands resulted in a sulfonamide substituted analogue with high affinity for the H4R. This moiety leads to improved physicochemical properties and is believed to probe a distinct H4R binding pocket that was previously identified using pharmacophore modeling. By introducing a variety of sulfonamide substituents, the H4R affinity was optimized. The interaction of the new ligands, in combination with a set of previously published quinazoline compounds, was described by a QSAR equation. Pharmacological studies revealed that the sulfonamide analogues have excellent H4R affinity and behave as inverse agonists at the human H4R. In vivo evaluation of the potent 2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline4-amino)-N- phenylethanesulfonamide (54) (pki = 8.31 ± 0.10) revealed it to have anti-inflammatory activity in an animal model of acute inflammation.

A new and facile synthesis of quinazoline-2,4(1 H,3H)-diones

Jiarong, Li,Xian, Chen,Daxin, Shi,Shuling, Ma,Qing, Li,Qi, Zhang,Jianhong, Tang

supporting information; body text, p. 1193 - 1196 (2009/08/07)

A new and facile preparation of quinazoline-2,4(1H,3H)-diones was first reported which was the condensation of aromatic o-aminonitriles with DMF or N,N-diethylformamide in the presence of ZnCl2 (0.5-10 mol %) at 190-200 °C in the sealed reactor

Quinazolines and related heterocyclic compounds and their therapeutic use

-

Page/Page column 18, (2009/07/18)

A compound of the formula wherein X is CR1 or N; Y is CR3 or N; R1, R3, R4, R5 and R6 are independently H, F, Cl, Br, I, or a hydrocarbon group which optionally contains one or more heteroatoms; R7 is a heterocyclic group including one or more N atoms; R' is Rx or NRyRz wherein Rx, Ry and Rz are each H or the same or different groups, including cyclic groups formed by Ry and Rz with the N atom, of up to 20 C atoms and optionally including up to 3 further heteroatoms selected from N, O and S; or a pharmaceutically acceptable salt, ester or solvate thereof, has therapeutic utility.

Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof

-

Page/Page column 66, (2009/04/24)

Substituted 4-amino-quinazoline compounds corresponding to formula I methods for their production, pharmaceutical compositions containing these compounds as active agents, and the uses thereof for treating or inhibiting disorders or disease states.

Novel benzopyrimidines as widened analogues of DNA bases

Lee, Alex H. F.,Kool, Eric T.

, p. 132 - 140 (2007/10/03)

(Chemical Equation Presented). We report on the synthesis, stacking, and pairing properties of a new structural class of size-expanded pyrimidine nucleosides, abbreviated dyT and dyC. Their bases are benzo-homologated variants of thymine and cytosine and

INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS

-

Page 183-184, (2008/06/13)

The present invention provides compounds of formula (I): These compounds, and pharmaceutically acceptable compositions thereof, are useful generally as kinase inhibitors, particularly as inhibitors of PRAK, GSK3, ERK2, CDK2, MK2, SRC, SYK, and Aurora-2. Accordingly, compounds and compositions of the invention are useful for treating or lessening the severity of a variety of disorders, including, but not limited to, heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, destructive bone disorders such as osteoporosis, proliferative disorders, infectious diseases and viral diseases.

Use of compounds for the elevation of pyruvate dehydrogenase activity

-

, (2008/06/13)

The use of compounds of the formula (I), and salts thereof; and pharmaceutically acceptable in vivo cleavable prodrugs of said compound of formula (I); and pharmaceutically acceptable salts of said compound or said prodrugs: wherein: Ring C is phenyl or a carbon linked heteroaryl ring substituted as defmed within; R1is an ortho substituent as defined within; n is 1 or 2; A—B is a linking group as defined within; R2and R3are as defined within; R4is hydroxy, hydrogen, halo, amino or methyl; in the manufacture of a medicament for use in the elevation of PDH activity in warm-blooded animals such as humans is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described.

4-aminoquinazoline derivatives

-

, (2008/06/13)

The compounds of the formula: STR1 wherein R1, Y, A, R4, n, Z, CyB, R3, and m are defined in the specification.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 16353-27-8